{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:34:49Z","timestamp":1785411289102,"version":"3.56.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F32AG072826"],"award-info":[{"award-number":["F32AG072826"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AG072958"],"award-info":[{"award-number":["P30AG072958"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01-AG-066597"],"award-info":[{"award-number":["P01-AG-066597"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1AG068063"],"award-info":[{"award-number":["RF1AG068063"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["AARG-22-924321"],"award-info":[{"award-number":["AARG-22-924321"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008539","name":"CurePSP","doi-asserted-by":"publisher","award":["656-2018-06"],"award-info":[{"award-number":["656-2018-06"]}],"id":[{"id":"10.13039\/100008539","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-024-01865-1","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T06:02:16Z","timestamp":1728712936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"12","author":[{"given":"Miles R.","family":"Bryan III","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Heng","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baggio A.","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey V.","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audra F.","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winifred","family":"Trotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,12]]},"reference":[{"key":"1865_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/ncomms1255","volume":"2","author":"TJ Cohen","year":"2011","unstructured":"Cohen TJ et al (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2:252","journal-title":"Nat Commun"},{"key":"1865_CR2","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/0896-6273(93)90057-X","volume":"10","author":"GT Bramblett","year":"1993","unstructured":"Bramblett GT et al (1993) Abnormal tau phosphorylation at Ser396 in alzheimer\u2019s disease recapitulates development and contributes to reduced microtubule binding. Neuron 10:1089\u20131099","journal-title":"Neuron"},{"key":"1865_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1083\/jcb.115.3.717","volume":"115","author":"KA Butner","year":"1991","unstructured":"Butner KA, Kirschner MW (1991) Tau protein binds to microtubules through a flexible array of distributed weak sites. J cell Biol 115:717\u2013730","journal-title":"J cell Biol"},{"key":"1865_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.410430209","volume":"43","author":"A Delacourte","year":"1998","unstructured":"Delacourte A, Sergeant N, Wattez A, Gauvreau D, Robitaille Y (1998) Vulnerable neuronal subsets in Alzheimer\u2019s and Pick\u2019s disease are distinguished by their \u03c4 isoform distribution and phosphorylation. Ann Neurol 43:193\u2013204","journal-title":"Ann Neurol"},{"key":"1865_CR5","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1046\/j.1471-4159.1999.0721243.x","volume":"72","author":"N Sergeant","year":"1999","unstructured":"Sergeant N, Wattez A, Delacourte A (1999) Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neurochem 72:1243\u20131249","journal-title":"J Neurochem"},{"key":"1865_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41593-018-0291-1","volume":"22","author":"H-U Klein","year":"2019","unstructured":"Klein H-U et al (2019) Epigenome-wide study uncovers large-scale changes in histone acetylation driven by tau pathology in aging and Alzheimer\u2019s human brains. Nat Neurosci 22:37\u201346","journal-title":"Nat Neurosci"},{"key":"1865_CR7","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1038\/s41467-021-22501-9","volume":"12","author":"B Caballero","year":"2021","unstructured":"Caballero B et al (2021) Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice. Nat Commun 12:2238","journal-title":"Nat Commun"},{"key":"1865_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3233\/JAD-190604","volume":"71","author":"CJ Huseby","year":"2019","unstructured":"Huseby CJ et al (2019) Quantification of tau protein lysine methylation in aging and Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 71:979\u2013991","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1865_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12964-021-00732-z","volume":"19","author":"AA Balmik","year":"2021","unstructured":"Balmik AA, Chinnathambi S (2021) Methylation as a key regulator of Tau aggregation and neuronal health in Alzheimer\u2019s disease. Cell Commun Signal 19:51","journal-title":"Cell Commun Signal"},{"key":"1865_CR10","doi-asserted-by":"publisher","first-page":"10825","DOI":"10.1074\/jbc.M512786200","volume":"281","author":"D Cripps","year":"2006","unstructured":"Cripps D et al (2006) Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation*. J Biol Chem 281:10825\u201310838","journal-title":"J Biol Chem"},{"key":"1865_CR11","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/0896-6273(93)90063-W","volume":"10","author":"M Morishima-Kawashima","year":"1993","unstructured":"Morishima-Kawashima M et al (1993) Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 10:1151\u20131160","journal-title":"Neuron"},{"key":"1865_CR12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s11064-015-1681-3","volume":"41","author":"WC Martins","year":"2016","unstructured":"Martins WC, Tasca CI, Cimarosti H (2016) Battling Alzheimer\u2019s disease: targeting SUMOylation-mediated pathways. Neurochem Res 41:568\u2013578","journal-title":"Neurochem Res"},{"key":"1865_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40478-019-0663-0","volume":"7","author":"M Qin","year":"2019","unstructured":"Qin M et al (2019) SET SUMOylation promotes its cytoplasmic retention and induces tau pathology and cognitive impairments. Acta Neuropathol Commun 7:21","journal-title":"Acta Neuropathol Commun"},{"key":"1865_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1083\/jcb.124.5.769","volume":"124","author":"B Goode","year":"1994","unstructured":"Goode B, Feinstein S (1994) Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol 124:769\u2013782","journal-title":"J Cell Biol"},{"key":"1865_CR15","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/nn.4067","volume":"18","author":"M Morris","year":"2015","unstructured":"Morris M et al (2015) Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci 18:1183\u20131189","journal-title":"Nat Neurosci"},{"key":"1865_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick AWP et al (2017) Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature 547:185\u2013190","journal-title":"Nature"},{"key":"1865_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.01.027","author":"T Arakhamia","year":"2020","unstructured":"Arakhamia T et al (2020) Posttranslational modifications mediate the structural diversity of tauopathy strains. Cell. https:\/\/doi.org\/10.1016\/j.cell.2020.01.027","journal-title":"Cell"},{"key":"1865_CR18","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1038\/s41467-020-19317-4","volume":"11","author":"H Trzeciakiewicz","year":"2020","unstructured":"Trzeciakiewicz H et al (2020) An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline. Nat Commun 11:5522","journal-title":"Nat Commun"},{"key":"1865_CR19","doi-asserted-by":"publisher","first-page":"16698","DOI":"10.1074\/jbc.RA119.009674","volume":"294","author":"D Ajit","year":"2019","unstructured":"Ajit D et al (2019) A unique tau conformation generated by an acetylation-mimic substitution modulates P301S-dependent tau pathology and hyperphosphorylation. J Biol Chem 294:16698\u201316711","journal-title":"J Biol Chem"},{"key":"1865_CR20","doi-asserted-by":"publisher","first-page":"15692","DOI":"10.1021\/bi061422+","volume":"45","author":"W Li","year":"2006","unstructured":"Li W, Lee VM-Y (2006) Characterization of two VQIXXK motifs for tau fibrillization in vitro \u2020. Biochemistry 45:15692\u201315701","journal-title":"Biochemistry"},{"key":"1865_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nchem.2889","volume":"10","author":"PM Seidler","year":"2018","unstructured":"Seidler PM et al (2018) Structure-based inhibitors of tau aggregation. Nat Chem 10:170\u2013176","journal-title":"Nat Chem"},{"key":"1865_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13024-016-0109-0","volume":"11","author":"PD Sohn","year":"2016","unstructured":"Sohn PD et al (2016) Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment. Mol Neurodegener 11:47","journal-title":"Mol Neurodegener"},{"key":"1865_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2016.03.005","volume":"90","author":"TE Tracy","year":"2016","unstructured":"Tracy TE et al (2016) Acetylated tau obstructs KIBRA-mediated signaling in synaptic plasticity and promotes tauopathy-related memory loss. Neuron 90:245\u2013260","journal-title":"Neuron"},{"key":"1865_CR24","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/nm.3951","volume":"21","author":"S-W Min","year":"2015","unstructured":"Min S-W et al (2015) Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 21:1154\u20131162","journal-title":"Nat Med"},{"key":"1865_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.032","author":"M-K Shin","year":"2021","unstructured":"Shin M-K et al (2021) Reducing acetylated tau is neuroprotective in brain injury. Cell. https:\/\/doi.org\/10.1016\/j.cell.2021.03.032","journal-title":"Cell"},{"key":"1865_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-020-00404-5","volume":"15","author":"GS Gibbons","year":"2020","unstructured":"Gibbons GS et al (2020) Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer\u2019s disease. Mol Neurodegener 15:64","journal-title":"Mol Neurodegener"},{"key":"1865_CR27","doi-asserted-by":"publisher","first-page":"e0218717","DOI":"10.1371\/journal.pone.0218717","volume":"14","author":"L Meyer","year":"2019","unstructured":"Meyer L et al (2019) A simplified workflow for monoclonal antibody sequencing. PLoS One 14:e0218717","journal-title":"PLoS One"},{"key":"1865_CR28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","volume":"67","author":"S-W Min","year":"2010","unstructured":"Min S-W et al (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67:953\u2013966","journal-title":"Neuron"},{"key":"1865_CR29","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1074\/jbc.M117.815357","volume":"293","author":"KH Strang","year":"2017","unstructured":"Strang KH et al (2017) Distinct differences in prion-like seeding and aggregation between tau protein variants provide mechanistic insights into tauopathies. J Biol Chem 293:2408\u20132421","journal-title":"J Biol Chem"},{"key":"1865_CR30","doi-asserted-by":"publisher","first-page":"35452","DOI":"10.1074\/jbc.M113.491001","volume":"288","author":"EE Congdon","year":"2013","unstructured":"Congdon EE, Gu J, Sait HBR, Sigurdsson EM (2013) Antibody uptake into neurons occurs primarily via clathrin-dependent Fc\u03b3 receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem 288:35452\u201335465","journal-title":"J Biol Chem"},{"key":"1865_CR31","doi-asserted-by":"publisher","first-page":"21652","DOI":"10.1074\/jbc.M115.657924","volume":"290","author":"KE Funk","year":"2015","unstructured":"Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI (2015) Distinct therapeutic mechanisms of tau antibodies: promoting microglial clearance versus blocking neuronal uptake. J Biol Chem 290:21652\u201321662","journal-title":"J Biol Chem"},{"key":"1865_CR32","doi-asserted-by":"publisher","first-page":"11161","DOI":"10.1038\/srep11161","volume":"5","author":"W Luo","year":"2015","unstructured":"Luo W et al (2015) Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci Rep 5:11161","journal-title":"Sci Rep"},{"key":"1865_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12974-022-02459-1","volume":"19","author":"IY Quiroga","year":"2022","unstructured":"Quiroga IY et al (2022) Synthetic amyloid beta does not induce a robust transcriptional response in innate immune cell culture systems. J Neuroinflamm 19:99","journal-title":"J Neuroinflamm"},{"key":"1865_CR34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s11481-021-10002-x","volume":"17","author":"DA Killebrew","year":"2022","unstructured":"Killebrew DA, Williams KS, Xie Y, Longo F, Meeker RB (2022) Suppression of HIV-associated macrophage activation by a p75 neurotrophin receptor ligand. J Neuroimmune Pharmacol 17:242\u2013260","journal-title":"J Neuroimmune Pharmacol"},{"key":"1865_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jim.2016.02.001","volume":"431","author":"N Nath","year":"2016","unstructured":"Nath N et al (2016) Homogeneous plate based antibody internalization assay using pH sensor fluorescent dye. J Immunol Methods 431:11\u201321","journal-title":"J Immunol Methods"},{"key":"1865_CR36","doi-asserted-by":"publisher","first-page":"44102","DOI":"10.1038\/srep44102","volume":"7","author":"H Trzeciakiewicz","year":"2017","unstructured":"Trzeciakiewicz H et al (2017) A dual pathogenic mechanism links tau acetylation to sporadic tauopathy. Sci Rep 7:44102","journal-title":"Sci Rep"},{"key":"1865_CR37","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.celrep.2017.07.082","volume":"20","author":"J-H Tseng","year":"2017","unstructured":"Tseng J-H et al (2017) The deacetylase HDAC6 mediates endogenous neuritic tau pathology. Cell Rep 20:2169\u20132183","journal-title":"Cell Rep"},{"key":"1865_CR38","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/brain\/aws013","volume":"135","author":"DJ Irwin","year":"2012","unstructured":"Irwin DJ et al (2012) Acetylated tau, a novel pathological signature in Alzheimer\u2019s disease and other tauopathies. Brain J Neurol 135:807\u2013818","journal-title":"Brain J Neurol"},{"key":"1865_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.10.029","author":"H Wesseling","year":"2020","unstructured":"Wesseling H et al (2020) Tau PTM profiles identify patient heterogeneity and stages of Alzheimer\u2019s disease. Cell. https:\/\/doi.org\/10.1016\/j.cell.2020.10.029","journal-title":"Cell"},{"key":"1865_CR40","doi-asserted-by":"publisher","first-page":"102697","DOI":"10.1016\/j.redox.2023.102697","volume":"62","author":"Q Liu","year":"2023","unstructured":"Liu Q et al (2023) Acetylated tau exacerbates learning and memory impairment by disturbing with mitochondrial homeostasis. Redox Biol 62:102697","journal-title":"Redox Biol"},{"key":"1865_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/hmg\/ddt402","volume":"23","author":"C Cook","year":"2014","unstructured":"Cook C et al (2014) Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet 23:104\u2013116","journal-title":"Hum Mol Genet"},{"key":"1865_CR42","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s42003-022-03373-1","volume":"5","author":"Y Xia","year":"2022","unstructured":"Xia Y et al (2022) Pathogenic tau recruits wild-type tau into brain inclusions and induces gut degeneration in transgenic SPAM mice. Commun Biol 5:446","journal-title":"Commun Biol"},{"key":"1865_CR43","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1523\/JNEUROSCI.2369-17.2018","volume":"38","author":"S-W Min","year":"2018","unstructured":"Min S-W et al (2018) SIRT1 deacetylates tau and reduces pathogenic tau spread in a mouse model of tauopathy. J Neurosci 38:3680\u20133688","journal-title":"J Neurosci"},{"key":"1865_CR44","doi-asserted-by":"publisher","first-page":"e0158470","DOI":"10.1371\/journal.pone.0158470","volume":"11","author":"TJ Cohen","year":"2016","unstructured":"Cohen TJ, Constance BH, Hwang AW, James M, Yuan C-X (2016) Intrinsic tau acetylation is coupled to auto-proteolytic tau fragmentation. PLoS One 11:e0158470","journal-title":"PLoS One"},{"key":"1865_CR45","first-page":"197","volume":"9","author":"SB Haeberlein","year":"2022","unstructured":"Haeberlein SB et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimer\u2019s Dis 9:197\u2013210","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"1865_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2022","unstructured":"van Dyck CH et al (2022) Lecanemab in early Alzheimer\u2019s disease. New Engl J Med 388:9\u201321","journal-title":"New Engl J Med"},{"key":"1865_CR47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40478-018-0585-2","volume":"6","author":"F Vitale","year":"2018","unstructured":"Vitale F et al (2018) Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. Acta Neuropathol Commun 6:82","journal-title":"Acta Neuropathol Commun"},{"key":"1865_CR48","doi-asserted-by":"publisher","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","volume":"27","author":"AA Asuni","year":"2007","unstructured":"Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27:9115\u20139129","journal-title":"J Neurosci"},{"key":"1865_CR49","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.neulet.2014.05.047","volume":"575","author":"KC Walls","year":"2014","unstructured":"Walls KC et al (2014) p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neurosci Lett 575:96\u2013100","journal-title":"Neurosci Lett"},{"key":"1865_CR50","doi-asserted-by":"publisher","first-page":"34457","DOI":"10.1074\/jbc.M111.229633","volume":"286","author":"X Chai","year":"2011","unstructured":"Chai X et al (2011) Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J Biol Chem 286:34457\u201334467","journal-title":"J Biol Chem"},{"key":"1865_CR51","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1523\/JNEUROSCI.4989-14.2015","volume":"35","author":"DL Castillo-Carranza","year":"2015","unstructured":"Castillo-Carranza DL et al (2015) Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer\u2019s disease mouse model. J Neurosci 35:4857\u20134868","journal-title":"J Neurosci"},{"key":"1865_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-018-0341-7","volume":"10","author":"C Dai","year":"2018","unstructured":"Dai C et al (2018) Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 \u00d7 Tg-AD mice. Alzheimer\u2019s Res Ther 10:13","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"1865_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108104","author":"LA Sandusky-Beltran","year":"2020","unstructured":"Sandusky-Beltran LA, Sigurdsson EM (2020) Tau immunotherapies: lessons learned, current status and future considerations. Neuropharmacology. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108104","journal-title":"Neuropharmacology"},{"key":"1865_CR54","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","volume":"16","author":"S-H Lee","year":"2016","unstructured":"Lee S-H et al (2016) Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement. Cell Rep 16:1690\u20131700","journal-title":"Cell Rep"},{"key":"1865_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JAD-2008-15202","volume":"15","author":"EM Sigurdsson","year":"2008","unstructured":"Sigurdsson EM (2008) Immunotherapy targeting pathological tau protein in Alzheimer\u2019s disease and related tauopathies. J Alzheimer\u2019s Dis 15:157\u2013168","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1865_CR56","doi-asserted-by":"publisher","DOI":"10.1172\/jci156537","author":"H-L Song","year":"2023","unstructured":"Song H-L et al (2023) Monoclonal antibody Y01 prevents tauopathy progression induced by lysine280-acetylated tau in cell and mouse models. J Clin Invest. https:\/\/doi.org\/10.1172\/jci156537","journal-title":"J Clin Invest"},{"key":"1865_CR57","doi-asserted-by":"publisher","first-page":"23645","DOI":"10.1074\/jbc.M703269200","volume":"282","author":"DP Hanger","year":"2007","unstructured":"Hanger DP et al (2007) Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis*. J Biol Chem 282:23645\u201323654","journal-title":"J Biol Chem"},{"key":"1865_CR58","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1074\/jbc.270.2.823","volume":"270","author":"M Morishima-Kawashima","year":"1995","unstructured":"Morishima-Kawashima M et al (1995) Proline-directed and Non-proline-directed Phosphorylation of PHF-tau (\u2217). J Biol Chem 270:823\u2013829","journal-title":"J Biol Chem"},{"key":"1865_CR59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13024-021-00460-5","volume":"16","author":"Y Xia","year":"2021","unstructured":"Xia Y, Prokop S, Giasson BI (2021) \u201cDon\u2019t Phos Over Tau\u201d: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer\u2019s disease and other tauopathies. Mol Neurodegener 16:37","journal-title":"Mol Neurodegener"},{"key":"1865_CR60","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/0896-6273(94)90264-X","volume":"13","author":"ES Matsuo","year":"1994","unstructured":"Matsuo ES et al (1994) Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer\u2019s disease paired helical filament tau. Neuron 13:989\u20131002","journal-title":"Neuron"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-024-01865-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-024-01865-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-024-01865-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T06:07:05Z","timestamp":1728713225000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-024-01865-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1186\/s40478-024-01865-1","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,12]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TJC and MRB are inventors of the ac-tau monoclonal antibodies described in this study, own the copyright, and could receive royalties. These relationships have been disclosed and are under management by UNC-Chapel Hill.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}